Serum NOS1AP concentration: association with clinical schizophrenia polymorphism and metabolic syndrome
OBJECTIVE: To study the associations of the serum concentration of NOS1AP (Nitric Oxide Synthase 1 Adaptor Protein) with clinical polymorphism and components of metabolic syndrome (MS) in patients with schizophrenia. MATERIAL AND METHODS: <0.05. RESULTS: =0.043). There were no statistically significant differences in NOS1AP levels depending on the presence of hypertension or dyslipidemia. CONCLUSION: The found patterns suggest a common pathophysiological mechanism mediated by NOS1AP linking psychopathology to metabolic disorders.
Authors
- Elena G. Kornetova (ORCID: https://orcid.org/0000-0002-5179-9727)
- Svetlana А. Ivanova (ORCID: https://orcid.org/0000-0001-7078-323X)
- Д.А. Петкун
- I. A. Mednova
- Y.V. Shternis (ORCID: https://orcid.org/0009-0006-7315-0984)
Institutions
- Siberian State Medical University (RU)
- Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences (RU)
- Tomsk National Research Medical Center (RU)
Publication Details
- Journal
- S S Korsakov Journal of Neurology and Psychiatry
- Published
- 2026-04-15
- DOI
- https://doi.org/10.17116/jnevro2026126031167
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00